Welcome to the Squeeze Project
The SQUEEZE consortium comprehensively addressed how biomarkers can be used to optimize disease modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis (RA). RA is a chronic immune-mediated disease with enormous health-related quality of life and socioeconomic impact. Through nine dedicated work packages SQUEEZE integrates to validate clinical, laboratory, molecular, digital and behavioural biomarkers to enable the recognition of patients with high likelihood of response to treatment and the selection of the drug with highest chance of benefit for an individual patient; and as such improve efficacy and safety of existing therapies (by squeezing the most out of existing drugs) in synergy with other EU-wide activities.
13 PARTNERS
10 COUNTRIES
€ 8 602 316,25
5 years
SQUEEZE project
We aim to have a real impact on life of people with rheumatoid arthritis

oUR NEWS
SQUEEZE featured in Trend
Our SQUEEZE project and coordinator Daniel Aletaha have been showcased in the Austrian magazine Trend! 👏 The article spotlights EU-funded initiatives in Austria and highlights the European Union's substantial commitment to research via the [...]
1st issue of our SQUEEZE newsletter published
We published the 1st issue of our SQUEEZE newsletter on our Linkedin channel!! 🗞️💊 On a bi-annual basis, we will publish insights into our daily collaboration within our 13 partners Horizon Europe funded project. [...]
SQUEEZE and PRP participation at EULAR 2023
SQUEEZE participation to the European Congress of Rheumatology EULAR 2023 was a success! First of all, congratulations to our SQUEEZE coordinator Daniel Aletaha for his appointment as president-elect of the EULAR - European Alliance [...]